Affinity stock

Private-market facts for current and former Affinity employees researching their stock.

Latest Round
Series C
Valuation
Not publicly disclosed
Founded
2014
Headquarters
San Francisco, CA
Founders
Ray Zhou, Shubham Goel
Status
private
Employees
2,256 -3% YoY
Total Raised
$120M

Talk to a Affinity stock specialist

Get personalized guidance on your Affinity shares — including current market activity, pricing context, and liquidity options.

Speak with an expert

Overview

Affinity is a relationship intelligence CRM that uses AI to automatically capture and analyze relationship data from emails and calendars, primarily serving venture capital, private equity, and investment banking firms.

Selling Affinity shares

Why shareholders consider selling

Shareholders in Affinity may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Affinity does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.

Can you sell Affinity stock?

Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Enterprise Software sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Affinity shares would be outlined in the holder's equity agreement or the company's governing documents.

What affects the value of Affinity shares?

The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Enterprise Software market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round can help frame expectations, though they do not guarantee a transaction price.

What should holders check before selling

Tools for Affinity shareholders

Exploring equity in Affinity often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.

Latest funding round

Affinity most recently raised a Series C round . Total funding raised to date is approximately $120M.

Lead investors in this round include Menlo Ventures and Advance Venture Partners.

Affinity IPO & exit outlook

Affinity has not announced a confirmed IPO date or acquisition. At the Series C stage, most companies are still years away from a public listing or acquisition. Founded 2014, Affinity has been private for 12 years.

For employees holding equity, the timeline to liquidity is uncertain. Options to consider include:

Read our liquidity guide for a full comparison of paths to liquidity.

Founders & company background

Affinity was founded in 2014 by Ray Zhou, Shubham Goel and is headquartered in San Francisco, CA.

Investors

Industry

Similar private companies

Latest Affinity news

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the 'Company” or 'Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company’s Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-stage kidney disease over a patient’s lifetime. Interim data from JUNIPER are expected in 2027.
The Manila TimesMay 26, 2026
Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity
Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity
Author summary Poly(ADP-ribose) polymerase (PARP) inhibitors are widely used anticancer drugs that target DNA repair mechanisms, particularly in tumors with BRCA mutations. However, most current inhibitors lack specificity and target both PARP1 and PARP2, which can lead to toxic side effects and limit their clinical benefit. In this study, we investigate the molecular basis of selective PARP1 inhibition, a key step toward designing safer and more effective therapies. Using advanced molecular simulations, we analyze how four clinically relevant inhibitors—two selective and two non-selective—interact with the PARP1 catalytic domain. Our results accurately reproduce experimental binding preferences and reveal that selectivity arises from a cooperative network of interactions, dominated by aromatic residues and electrostatic contacts. These interactions form a multivalent binding environment that stabilizes selective inhibitors more effectively. Additionally, by introducing targeted mutations in the binding site, we demonstrate how specific amino acids contribute to both binding strength and the pathway by which inhibitors associate with the protein. Overall, our findings provide a detailed mechanistic understanding of PARP1 selectivity and offer valuable insights for the rational design of improved anticancer drugs.
PLOS (Public Library of Science)May 26, 2026
More Singapore residents identifying with English or Singlish, as mother tongue affinity falls: IPS survey
More Singapore residents identifying with English or Singlish, as mother tongue affinity falls: IPS survey
The survey of 4,000 residents finds nearly half identified most with English or Singlish, up from one-third a decade ago.
CNAMay 25, 2026

Talk to a Affinity stock specialist

Get personalized guidance on your Affinity shares — including current market activity, pricing context, and liquidity options.

Speak with an expert

Frequently asked questions

Is Affinity a public or private company?
Affinity is a private company as of the most recent data available. Its shares do not trade on a public stock exchange. Employees and early shareholders who want liquidity may need to explore secondary-market options or wait for a future IPO or acquisition.
What is Affinity's valuation?
Affinity's valuation has not been publicly disclosed. Private company valuations are typically set during funding rounds and are not always reported publicly.
What is Affinity's stock price per share?
Affinity does not trade on a public exchange, so there is no single live stock price. Indicative pricing may be available through secondary-market platforms. The most recent known valuation data can help frame expectations, but common shares typically trade at a discount to the headline preferred-stock valuation.
When will Affinity IPO?
Affinity has not announced a confirmed IPO date. IPO timing depends on market conditions, company financials, and board decisions. Employees should plan around the possibility that liquidity may take years and consider whether secondary-market options or company-sponsored tender offers are available in the interim.
Can I sell my Affinity stock?
It depends on what you hold and your company's policies. Vested, exercised shares are generally eligible for secondary-market sales, subject to Affinity's transfer restrictions and right of first refusal (ROFR). Unexercised options and unvested RSUs typically cannot be sold. Some companies also run periodic tender offers that allow employees to sell a portion of their holdings at a set price. Check your equity agreement or speak with your stock plan administrator for Affinity-specific rules.
How much does it cost to exercise Affinity stock options?
The out-of-pocket cost equals your strike price multiplied by the number of shares you exercise. For ISOs, exercising may also trigger the Alternative Minimum Tax (AMT) based on the spread between your strike price and the current fair market value. For NSOs, the spread is taxed as ordinary income at exercise. Use our AMT Calculator and Stock Option Tax Calculator to model the cost for your specific situation.
What type of stock options does Affinity grant — ISOs or NSOs?
Most venture-backed companies grant ISOs (Incentive Stock Options) to U.S. employees where possible, with NSOs (Non-Qualified Stock Options) used for amounts exceeding the $100K annual ISO limit, for contractors, or for non-U.S. employees. Your specific grant type is listed in your option agreement. The distinction matters because ISOs can qualify for long-term capital gains treatment, while NSOs are taxed as ordinary income at exercise. See our ISO guide and NSO guide for the full breakdown.
What happens to my Affinity stock if the company is acquired?
In an acquisition, your equity outcome depends on the deal structure and your grant terms. Common scenarios include cash-out (your shares are bought at a set price per share), rollover (your shares convert into the acquirer's equity), or cancellation with an acceleration clause. If you have double-trigger acceleration, your unvested shares may accelerate only if you are also terminated. The liquidation preference stack determines how proceeds are divided — preferred shareholders are paid first, which can reduce or eliminate the payout to common shareholders in lower-value exits.
What is the difference between common and preferred Affinity stock?
Employees typically hold common stock (or options on common stock). Investors hold preferred stock, which usually comes with a liquidation preference — meaning investors get paid first in an exit before common shareholders receive anything. This distinction is critical when estimating what your shares might actually be worth in an exit.
What happens to my Affinity options if I leave?
When you leave a company, you typically have a limited post-termination exercise window — often 90 days — to exercise your vested options or they expire worthless. Some companies offer extended windows (up to 10 years). Unvested options are forfeited. If you hold ISOs and don't exercise within 90 days of leaving, they convert to NSOs, which changes the tax treatment. Review your option agreement for Affinity's specific terms, and use our Exercise Timing Planner to model the financial tradeoffs.

Related pages

Last verified: 2026-05-28 · Affinity data compiled from funding disclosures, investor announcements, corporate filings, and public records.

Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.